A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma-Reference-Cited by-同舟云学术

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma

Published:2022-06-30 Issue:8 Volume:113 Page:2798-2806
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Yamazaki Naoya¹^ORCID,Isei Taiki²,Kiyohara Yoshio³,Koga Hiroshi⁴,Kojima Takashi⁵^ORCID,Takenouchi Tatsuya⁶,Yokota Kenji⁷,Namikawa Kenjiro¹^ORCID,Yi Min⁸,Keegan Alissa⁸,Fukushima Satoshi⁹^ORCID

Affiliation:

1. Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan

2. Department of Dermatologic Oncology Osaka International Cancer Institute Osaka Japan

3. Division of Dermatology Shizuoka Cancer Center Hospital Shizuoka Japan

4. Department of Dermatology Shinshu University School of Medicine Matsumoto, Nagano Japan

5. Department of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East Kashiwa‐shi, Chiba Japan

6. Division of Dermatology Niigata Cancer Center Hospital Niigata‐shi, Niigata Japan

7. Department of Dermatology Nagoya University Hospital Nagoya‐shi, Aichi Japan

8. Amgen Inc. Thousand Oaks California USA

9. Department of Dermatology and Plastic Surgery Faculty of Life Sciences Kumamoto University Kumamoto Japan

Funder

Amgen

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15450

Reference30 articles.

1. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036

2. Cancer Statistics, 2021

3. Targeted Therapy and Immunotherapy for Melanoma in Japan

4. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care

5. Characteristics of melanoma in Japan: a nationwide registry analysis 2011–2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

2. Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review;Frontiers in Oncology;2024-07-16

3. Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?;Pharmaceuticals;2024-07-09

4. TIGIT, a novel immune checkpoint therapy for melanoma;Cell Death & Disease;2023-07-26

5. Oncolytic virotherapy: basic principles, recent advances and future directions;Signal Transduction and Targeted Therapy;2023-04-11